Multicohort Study of BFTAF as First-Line HIV Treatment at a Public Hospital in Eastern China

What this Trial Is About

This research aims to gather real-world evidence on the use of bictegraviremtricitabinetenofovir alafenamide BFTAF as a first-line antiretroviral therapy ART for adults newly diagnosed with HIV, including those with advanced disease. The study addresses limited clinical data and cost concerns related to BFTAF, involving 630 patients divided into six cohorts based on diagnosis time and treatment regimen. It is a multicohort observational study conducted in China at the Designated Hospital for HIVAIDS Treatment of Nantong City. Participants include both prospective patients initiating BFTAF between July 2024 and June 2025 and retrospective patients previously treated with either tenofovirlamivudineefavirenz TDF3TCEFV or dolutegravirlamivudine DTG3TC from January 2020 to June 2023. The study compares clinical outcomes and cost-effectiveness across these groups. The ART regimens are taken once daily with specified tablet doses for each treatment group. Participants will be monitored over 48 weeks with data collected from electronic health records and patient-reported outcomes. Assessments include viral load suppression, CD4 count changes, immune recovery, treatment adherence, adverse events, quality of life, and mental and cardiovascular health. Cost data and modeling will evaluate long-term economic outcomes. The study includes up to 104 weeks of monitoring for treatment discontinuation and adverse events.

Good-first: B/F/TAF As First-line ART